ALPS Advisors’s Akcea Therapeutics Inc AKCA Stock Holding History

ALPS Advisors’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-129,589	Closed	-$2.35M	–	902
2020 Q3	$2.35M	Sell	129,589 -8,889	-6%	-$126K	0.03%	214
2020 Q2	$1.9M	Sell	138,478 -32,242	-19%	-$497K	0.03%	243
2020 Q1	$2.44M	Sell	170,720 -18,404	-10%	-$302K	0.04%	192
2019 Q4	$3.2M	Buy	189,124 +3,626	+2%	+$67.5K	0.03%	189
2019 Q3	$2.85M	Sell	185,498 -7,877	-4%	-$168K	0.02%	185
2019 Q2	$4.54M	Buy	+193,375	New	+$4.78M	0.03%	160
2018 Q4	–	Sell	-151,688	Closed	-$5.31M	–	982
2018 Q3	$5.31M	Buy	151,688 +28,320	+23%	+$857K	0.03%	159
2018 Q2	$2.92M	Buy	+123,368	New	+$2.94M	0.02%	203

ALPS Advisors's AKCA Position: Q4 2020 in Review

ALPS Advisors sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 129,589 shares — an estimated $2.35M sold.

ALPS Advisors first reported a position in AKCA in Q2 2018 and held it in 8 quarters. The position peaked at $5.31M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

ALPS Advisors reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
ALPS Advisors sold 129,589 Akcea Therapeutics Inc shares in Q4 2020, an estimated $2.35M.
ALPS Advisors first reported a position in Akcea Therapeutics Inc in Q2 2018 and held it in 8 quarters.
ALPS Advisors's Akcea Therapeutics Inc position peaked at $5.31M in Q3 2018.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on ALPS Advisors's 13F filing for Q4 2020, filed 3 Feb 2021.